Ramsay Générale de Santé SA reported interim results for the nine-month period ending March 31, 2025, with group revenue reaching €3.889 billion, marking a 5.1% increase compared to the previous year. This growth was supported by activity volume growth and the acquisition of Cosem primary care centers in June 2024. On a like-for-like basis, revenue grew by 3.2%. The group's EBITDA was nearly stable at €441 million, showing a slight decrease of 0.8% or €3.6 million compared to the same period last year. This stability absorbed the impact of the French government's withholding of the prudential coefficient, reduced subsidies, increased salaries, and procurement inflation. Net cash flow from operating activities decreased by €50 million to €282 million, largely due to the repayment of French government cash advances and working capital timing differences. Reported net financial debt stood at €3.859 billion as of March 31, 2025, with a restated net leverage of 5.7x. CEO Pascal Roché highlighted that the group's EBITDA was affected by a €25 million reduction in the French government's revenue guarantee, a €14.7 million price decrease due to withholding of the prudential coefficient, and the absence of a €17 million inflation grant received in the previous year. The group continues to focus on cash flow generation through operational efficiency and working capital improvement. Additionally, Ramsay Santé is expanding day hospitals in France to align with patients' healthcare needs, aiming for future profitable growth.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。